
Gensight Biologics SA
PAR:SIGHT

Balance Sheet
Balance Sheet Decomposition
Gensight Biologics SA
Current Assets | 13m |
Cash & Short-Term Investments | 6.9m |
Receivables | 1.3m |
Other Current Assets | 4.7m |
Non-Current Assets | 2m |
Long-Term Investments | 519k |
PP&E | 1.4m |
Intangibles | 66k |
Balance Sheet
Gensight Biologics SA
Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||
Cash & Cash Equivalents |
11
|
30
|
54
|
55
|
26
|
19
|
38
|
44
|
11
|
2
|
|
Cash |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
11
|
2
|
|
Cash Equivalents |
9
|
30
|
54
|
55
|
26
|
19
|
38
|
44
|
0
|
0
|
|
Short-Term Investments |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Receivables |
2
|
4
|
3
|
5
|
5
|
6
|
4
|
5
|
4
|
2
|
|
Accounts Receivables |
1
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
|
Other Receivables |
1
|
4
|
3
|
5
|
5
|
6
|
4
|
4
|
4
|
2
|
|
Other Current Assets |
0
|
1
|
1
|
1
|
3
|
2
|
2
|
4
|
9
|
2
|
|
Total Current Assets |
14
|
35
|
58
|
61
|
35
|
28
|
44
|
53
|
23
|
7
|
|
PP&E Net |
0
|
1
|
1
|
1
|
1
|
4
|
3
|
3
|
2
|
2
|
|
PP&E Gross |
0
|
1
|
1
|
1
|
1
|
4
|
3
|
3
|
2
|
2
|
|
Accumulated Depreciation |
0
|
0
|
0
|
1
|
1
|
2
|
3
|
4
|
5
|
4
|
|
Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
|
Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Assets |
15
N/A
|
36
+145%
|
59
+63%
|
62
+5%
|
37
-41%
|
32
-12%
|
47
+46%
|
57
+20%
|
26
-54%
|
9
-65%
|
|
Liabilities | |||||||||||
Accounts Payable |
2
|
5
|
2
|
2
|
8
|
7
|
8
|
12
|
8
|
6
|
|
Accrued Liabilities |
1
|
1
|
1
|
2
|
2
|
2
|
3
|
2
|
4
|
2
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
1
|
3
|
5
|
2
|
17
|
|
Other Current Liabilities |
1
|
1
|
0
|
0
|
0
|
2
|
4
|
3
|
1
|
0
|
|
Total Current Liabilities |
4
|
6
|
3
|
4
|
10
|
12
|
17
|
22
|
15
|
25
|
|
Long-Term Debt |
1
|
1
|
3
|
3
|
3
|
10
|
16
|
12
|
15
|
6
|
|
Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
6
|
11
|
8
|
|
Total Liabilities |
4
N/A
|
7
+65%
|
6
-16%
|
7
+23%
|
13
+82%
|
22
+68%
|
36
+62%
|
41
+14%
|
41
+1%
|
40
-3%
|
|
Equity | |||||||||||
Common Stock |
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
|
Retained Earnings |
9
|
21
|
38
|
58
|
89
|
118
|
142
|
166
|
198
|
223
|
|
Additional Paid In Capital |
19
|
50
|
91
|
112
|
112
|
128
|
153
|
181
|
181
|
191
|
|
Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Equity |
11
N/A
|
29
+177%
|
53
+82%
|
55
+3%
|
24
-57%
|
11
-56%
|
12
+12%
|
16
+36%
|
15
N/A
|
31
-101%
|
|
Total Liabilities & Equity |
15
N/A
|
36
+145%
|
59
+63%
|
62
+5%
|
37
-41%
|
32
-12%
|
47
+46%
|
57
+20%
|
26
-54%
|
9
-65%
|
|
Shares Outstanding | |||||||||||
Common Shares Outstanding |
14
|
14
|
19
|
24
|
24
|
33
|
41
|
46
|
46
|
65
|